Patents Assigned to Seikagaku Corporation
  • Patent number: 10953037
    Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • Patent number: 10955413
    Abstract: An object of the present invention is to provide means for correctly measuring zygomycota. The present inventors have found that conventionally difficult zygomycota measurement can be performed through subjecting an untreated specimen to an acid treatment. The present invention provides a method for measuring zygomycota, the method including measuring zygomycota in a specimen that was subjected to an acid treatment; an agent for preparing a specimen for measurement of zygomycota; a method for preparing a specimen for measurement of zygomycota; and a reagent kit for measuring zygomycota.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Maki Aizawa, Koichi Makimura
  • Publication number: 20210069235
    Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 11, 2021
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Kazuyuki KANO, Yuji NOBUOKA, Takayuki SEO
  • Publication number: 20210052634
    Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 25, 2021
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Sho FUNAYAMA, Risa NODERA, Takahiro HATANAKA
  • Publication number: 20210052633
    Abstract: The present application provides: a technique for promoting hyaluronic acid synthesis by hyaluronic acid-producing cells; a method for evaluating the responsiveness of hyaluronic acid-producing cells to a compound; or a method for evaluating the responsiveness of a polysaccharide derivative represented by formula 1 in the description or a salt thereof to hyaluronic acid-producing cells. By bringing a polysaccharide derivative represented by formula 1 in the description or a salt thereof into contact with hyaluronic acid-producing cells, promotion of hyaluronic acid synthesis is achieved in the hyaluronic acid-producing cells. Further, by using the polysaccharide derivative or a salt thereof for hyaluronic acid-producing cells, the responsiveness of the hyaluronic acid-producing cells can be evaluated using the production of hyaluronic acid as an index.
    Type: Application
    Filed: March 26, 2019
    Publication date: February 25, 2021
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Tomochika KISUKEDA, Keiji YOSHIOKA
  • Patent number: 10925839
    Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. Specifically provided is a composition for treating joint diseases that obtains higher efficacy than prior preparations by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is targeted at patients with human joint diseases who have a BMI of 25 kg/m2 or higher.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Kazuyuki Kano, Yuji Nobuoka, Takayuki Seo
  • Patent number: 10919840
    Abstract: The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 16, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Sho Funayama, Yosuke Yasuda, Akihiro Takezawa, Katsuya Takahashi
  • Publication number: 20210015933
    Abstract: Provided are a novel conjugate of a bioactive carboxylic acid type compound with a polymer having a carboxy group, represented by Formula (I) as defined in the specification, capable of finely controlling a sustained release rate, and capable of sustainably releasing even a drug in which the vicinity of a carbonyl group of the bioactive carboxylic acid type compound is sterically crowded, and a method for manufacturing the same.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Applicant: Seikagaku Corporation
    Inventors: Nobuo Kobayashi, Kenta Adachi, Kenichi Namatsu
  • Patent number: 10883963
    Abstract: The present invention addresses the problem of providing a means for making highly sensitive and stable measurements possible using electrochemical measurement methods. This problem is resolved by providing: a labeling substance represented by general formula (1) and used to label a substrate; a measurement substrate that is formed by being labeled using the labeling substance; a method of measuring using electrochemical measurement methods that use the measurement substrate; and a reagent kit that includes as components the labeling substance and/or the measurement substrate. (In general formula (1), R1 is either H or an alkyl group (CmH2m+1), m is an integer of 1-4, R2 is an alkyl group (CnH2n+1), and n is an integer of 1-4.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 5, 2021
    Assignees: SEIKAGAKU CORPORATION, TOHOKU UNIVERSITY
    Inventors: Hikaru Mizumura, Toshio Oda, Tomokazu Matsue, Kumi Inoue
  • Publication number: 20200397876
    Abstract: There are provided a pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/?g as an active ingredient, and containing the saccharide-degrading enzyme in an amount of not less than 2 ?g and not more than 8 ?g.
    Type: Application
    Filed: February 27, 2019
    Publication date: December 24, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Mine HIGUCHI
  • Publication number: 20200397703
    Abstract: There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.
    Type: Application
    Filed: February 27, 2019
    Publication date: December 24, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Mine HIGUCHI
  • Patent number: 10835554
    Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 17, 2020
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Kazuyuki Kano, Yuji Nobuoka, Takayuki Seo
  • Publication number: 20200352882
    Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. Specifically provided is a composition for treating joint diseases that obtains higher efficacy than prior preparations by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is targeted at patients with human joint diseases who have a BMI of 25 kg/m2 or higher.
    Type: Application
    Filed: March 14, 2018
    Publication date: November 12, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Kazuyuki KANO, Yuji NOBUOKA, Takayuki SEO
  • Publication number: 20200345760
    Abstract: The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. The present invention also relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutical acceptable carrier.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 5, 2020
    Applicant: Seikagaku Corporation
    Inventors: Eiji NOGAMI, Akira KOUSHINBOU, Noriko OSHIMA, Kota FUJIWARA, Tomoya SATO
  • Publication number: 20200338113
    Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Masamichi YAMADA, Chiyo Sakenaga, Keiichiro Arai, Kazutaka Yamamoto
  • Publication number: 20200330503
    Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 22, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Masamichi Yamada, Chiyo Sakenaga, Keiichiro Arai, Kazutaka Yamamoto
  • Publication number: 20200281814
    Abstract: A main object of the present disclosure is to provide a drug storage container enabling simple and reliable preparation of a mixed solution containing a drug and an auxiliary agent, a closing member that is for use in the drug storage container and configured to detachably retain a solid preparation containing a drug or an auxiliary agent, a method for manufacture of the drug storage container, a microbial contaminant test method using the drug storage container, and a solid preparation for preparing a buffer solution.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 10, 2020
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Masanao WATANABE, Makoto ISHII, Toshio ODA, Hikaru MIZUMURA
  • Patent number: 10716804
    Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 21, 2020
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Sho Funayama
  • Publication number: 20200206323
    Abstract: A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 2, 2020
    Applicants: THE NEMOURS FOUNDATION, SEIKAGAKU CORPORATION
    Inventors: Shunji TOMATSU, Kazuki SAWAMOTO, Takehiko NAKAMURA, Ikue KITAZAWA, Hideyuki FUTATSUMORI
  • Patent number: D895110
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: September 1, 2020
    Assignees: Taisei Kako Co., Ltd., Seikagaku Corporation
    Inventors: Norimasa Takada, Tomoyuki Sonoyama